| Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy D Morales, A Pacurariu, J Slattery, L Pinheiro, P McGettigan, X Kurz JAMA neurology 76 (7), 827-833, 2019 | 78 | 2019 |
| Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone/corticosteroid therapy: population-based nested case–control study DR Morales, J Slattery, A Pacurariu, L Pinheiro, P McGettigan, X Kurz Clinical drug investigation 39, 205-213, 2019 | 77 | 2019 |
| Cohort study of psychiatric adverse events following exposure to levonorgestrel-containing intrauterine devices in UK general practice J Slattery, D Morales, L Pinheiro, X Kurz Drug Safety 41, 951-958, 2018 | 23 | 2018 |
| Indications for systemic fluoroquinolone therapy in Europe and prevalence of primary-care prescribing in France, Germany and the UK: descriptive population-based study DR Morales, J Slattery, L Pinheiro, X Kurz, K Hedenmalm Clinical drug investigation 38, 927-933, 2018 | 15 | 2018 |
| An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance LC Pinheiro, G Candore, C Zaccaria, J Slattery, P Arlett Pharmacoepidemiology and Drug Safety 27 (1), 38-45, 2018 | 15 | 2018 |
| Geographical variation in reporting interstitial lung disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance L Pinheiro, K Blake, J Januskiene, QY Yue, P Arlett Pharmacoepidemiology and drug safety 25 (6), 705-712, 2016 | 9 | 2016 |
| Artificial intelligence in European medicines regulation PA Hines, R Herold, L Pinheiro, Z Frias, P Arlett Nature Reviews Drug Discovery 22 (2), 81-82, 2023 | 7 | 2023 |
| Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice J Slattery, C Quinten, G Candore, L Pinheiro, R Flynn, X Kurz, H Nordeng British journal of clinical pharmacology 88 (10), 4526-4539, 2022 | 7 | 2022 |
| An application of machine learning in pharmacovigilance: estimating likely patient genotype from phenotypical manifestations of fluoropyrimidine toxicity L Correia Pinheiro, J Durand, JM Dogné Clinical Pharmacology & Therapeutics 107 (4), 944-947, 2020 | 6 | 2020 |
| Artificial intelligence in pharmacovigilance: a regulatory perspective on explainability LC Pinheiro, X Kurz Pharmacoepidemiol Drug Saf 31 (12), 1308-1310, 2022 | 3 | 2022 |
| Identifiability of biologicals: an analysis using the EMA adverse drug reaction database, EudraVigilance LC Pinheiro, TJ Giezen, E Wolff-Holz, M Weise, A Laslop, ... Clin Pharmacol Ther 10, 2021 | 3 | 2021 |
| Correction to: relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone/corticosteroid therapy: population-based nested case–control study DR Morales, J Slattery, A Pacurariu, L Pinheiro, P McGettigan, X Kurz Clinical Drug Investigation 39, 215-215, 2019 | 3 | 2019 |
| Standardised and reproducible phenotyping using distributed analytics and tools in the Data Analysis and Real World Interrogation Network (DARWIN EU®) DP Alhambra, F Dernie, G Corby, A Robinson, J Bezer, R Parry, ... | | 2024 |
| Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions L Correia Pinheiro, TJ Giezen, E Wolff‐Holz, M Weise, A Laslop, ... Clinical Pharmacology & Therapeutics 110 (5), 1311-1317, 2021 | | 2021 |
| Investigation of psychiatric adverse events following exposure to levonorgestrel containing IUDs J Slattery, D Morales, L Pinheiro, X Kurz PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 27, 217-217, 2018 | | 2018 |
| Association between systemic fluoroquinolone exposure and peripheral neuropathy: Population-based nested case-control study DR Morales, J Slattery, A Pacurariu, L Pinheiro, X Kurz PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 27, 337-338, 2018 | | 2018 |
| Clinical Indications for Fluoroquinolones in Routine Care DR Morales, J Slattery, X Kurz, L Pinheiro, K Hedenmalm PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 26, 595-596, 2017 | | 2017 |
| The New Definition of an Adverse Drug Reaction (ADR) with Focus on Abuse/Misuse: The Example of Pregabalin I Skibicka-Stepien, A Lazowska, S Brosch, T Goedecke, V Newbould, ... DRUG SAFETY 38 (10), 1027-1027, 2015 | | 2015 |
| A cohort study of psychiatric adverse events following exposure to J Slattery, D Morales, L Pinheiro, X Kurz Gynecological Endocrinology 25 (10), 2009 | | 2009 |
| Vigilância Activa de Eventos Após Vacinação LC Pinheiro PQDT-Global, 2008 | | 2008 |
